ANI Pharmaceuticals (ANIP) vs Biohaven (BHVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
ANI Pharmaceuticals (ANIP) has outperformed Biohaven (BHVN) over the past year, losing 18.6% versus a loss of 29.9%. Biohaven is the larger company by market cap ($1.82 billion vs $1.70 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIP | BHVN |
|---|---|---|
| Share price | $73.89 | $12.08 |
| Market cap | $1.70B | $1.82B |
| 1-day change | +2.65% | +1.26% |
| YTD return | -6.40% | +7.00% |
| 1-year return | -18.61% | -29.89% |
| 5-year return | +91.72% | — |
| P/E ratio (TTM) | 15.99 | — |
| Forward P/E | 7.27 | — |
| EPS (TTM) | $4.62 | $-4.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $883.37M | — |
| Revenue growth (YoY) | +43.78% | — |
| Net income (latest FY) | $78.34M | $-738.82M |
| Gross margin | 61.36% | — |
| Operating margin | 12.58% | — |
| Net margin | 8.87% | — |
| 52-week high | $97.00 | $18.57 |
| 52-week low | $69.58 | $7.48 |
| Distance from 52-week high | -23.82% | -34.93% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +43.16% | +76.08% |
| Average volume | 376.38K | 2.63M |
| Shares outstanding | 22.96M | 151.04M |
| Employees | 970 | 274 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANIP has outperformed BHVN by 11.3 percentage points over the past year.
- The two companies sit in different sectors: ANI Pharmaceuticals in Health Care and Biohaven in Healthcare.
About ANI Pharmaceuticals
ANIP stock →ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.
Health Care · Biotechnology: Pharmaceutical Preparations · 970 employees
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Healthcare · Biotechnology · 274 employees
ANIP vs BHVN FAQ
Which is bigger, ANI Pharmaceuticals or Biohaven?
Biohaven (BHVN) is larger, with a market capitalization of $1.82B compared with $1.70B for ANI Pharmaceuticals (ANIP).
Which stock has performed better over the past year, ANIP or BHVN?
ANIP returned -18.61% over the past 12 months, compared with -29.89% for BHVN (price return, excluding dividends). Past performance does not predict future results.
Are ANI Pharmaceuticals and Biohaven in the same industry?
No. ANI Pharmaceuticals is in the Health Care sector, while Biohaven is in Healthcare.